Related Experiment Video
Updated: Jun 22, 2026
16:24
Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells
Published on: February 21, 2014
Using a global proteomic approach to identify proteins affected by estrogen therapy
1Laboratory of Proteomics and Analytical Technologies, Advanced Technology Program, SAIC-Frederick Inc, National Cancer Institute at Frederick, Frederick, MD 21702, USA. veenstra@ncifcrf.gov.
Genome Medicine
|June 13, 2009
Summary
Discovery-driven proteomic studies aim to find novel biological insights. However, current technologies limit comprehensive proteome analysis, hindering widespread adoption in clinical research.
Area of Science:
- Proteomics
- Systems Biology
- Biotechnology
Background:
- Increasing technological capabilities enable large-scale, unbiased biological molecule measurement.
- Discovery-driven studies generate vast datasets for novel finding detection.
- Proteomics presents unique challenges due to the lack of technology for complete proteome visualization.
Discussion:
- Non-biased proteomic studies require validated methods for accurate difference detection.
- Limited sample availability in clinical and epidemiological studies exacerbates these challenges.
- Demonstrating the reliability of these methods is crucial for routine adoption.
Key Insights:
- Current proteomic technologies do not offer a complete view of the proteome.
- Accurate detection of proteomic differences is essential for non-biased studies.
- Validation is needed before widespread use in clinical and epidemiological research.
Outlook:
- Advancements in proteomic technologies are needed for comprehensive analysis.
- Standardization and validation of non-biased methods will drive adoption.
- Future research should focus on overcoming limitations for clinical applications.
